Komori
Governance4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Notice Concerning Partial Amendments to the Articles of Incorporation

Subject to approval at the General Meeting of Shareholders, the Company will transition from a company with a board of company auditors to a company with an Audit & Supervisory Committee. Accordingly, provisions concerning the Audit & Supervisory Committee and directors who are Audit & Supervisory Committee members will be added to the Articles of Incorporation, while provisions concerning company auditors and the Board of Company Auditors will be deleted. The effective date is scheduled for 25 June 2026.

Worth reading
70In focus
Scored from 2 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

Current: Company with a Board of Corporate Auditors. Proposed change: Company with an Audit and Supervisory Committee (scheduled for 25 June 2026)
Number of directorsProposed change: No more than 6 directors excluding directors who are Audit & Supervisory Committee members, and no more than 5 directors who are Audit & Supervisory Committee members. Number of outside directors: Not disclosed
Committee1
Audit and Supervisory Committee. Proportion of outside members: 非開示. Nomination Committee and Compensation Committee: 非開示
Changes this time

The Company will transition from a company with a Board of Company Auditors to a company with an Audit & Supervisory Committee. Provisions concerning Audit & Supervisory Committee members and the Audit & Supervisory Committee will be added, and provisions concerning company auditors and the Board of Company Auditors will be deleted. Directors will be elected separately as directors who are Audit & Supervisory Committee members and other directors, and their compensation will also be determined separately.

Governance structure
ItemDetails
Corporate Governance StructureCurrent: Company with a Board of Corporate Auditors. Proposed change: Company with an Audit and Supervisory Committee (scheduled for 25 June 2026)
Number of directorsProposed change: No more than 6 directors excluding directors who are Audit & Supervisory Committee members, and no more than 5 directors who are Audit & Supervisory Committee members. Number of outside directors: Not disclosed
CommitteeAudit and Supervisory Committee. Proportion of outside members: Not disclosed. Nomination Committee and Compensation Committee: Not disclosed
Changes this timeThe Company will transition from a company with a Board of Company Auditors to a company with an Audit & Supervisory Committee. Provisions concerning Audit & Supervisory Committee members and the Audit & Supervisory Committee will be added, and provisions concerning company auditors and the Board of Company Auditors will be deleted. Directors will be elected separately as directors who are Audit & Supervisory Committee members and other directors, and their compensation will also be determined separately.
Items this document does not state (4)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen the Board of Directors’ supervisory function, enhance and reinforce corporate governance, achieve sustainable growth in corporate value, and accelerate management decision-making and execution.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning Partial Amendments to the Articles of Incorporation | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori